Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA9 | Q16790 | 3/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5515628 | 0.72 | CA2 (0.37) | CA1CA2CA9CA12CA14 | |
| SCHEMBL29419597 | 0.70 | ALDH1A1 (0.32) | ALDH1A1POLB | |
| SCHEMBL9356255 | 0.70 | — | — | |
| SCHEMBL5517761 | 0.69 | CA1 (0.42) | OPRD1CA1CA2CA9CA12 | |
| SCHEMBL5509508 | 0.69 | OPRD1 (0.49) | OPRD1CA1CA2CA9CA12 | |
| SCHEMBL22781498 | 0.69 | — | — | |
| SCHEMBL5515853 | 0.66 | CA2 (0.37) | CA1CA2CA9CA12CA14 | |
| SCHEMBL23531739 | 0.64 | CA2 (0.43) | OPRD1CA1CA2CA9CA12 | |
| SCHEMBL31488146 | 0.63 | OPRD1 (0.40) | OPRD1CA1CA2CA9 | |
| SCHEMBL6968712 | 0.63 | OPRD1 (0.33) | OPRD1CA1CA2CA9CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7250430-B2 | Thiophene-and thiazolesulfonamides as antineoplastic agents | ELI LILLY AND COMPANY (US) | 2007-07-31 | — | — | US | disclosed |
| US-20060223871-A1 | Thiophene-and thiazolesulfonamides as antineoplastic agents | GROSSMAN CORA S | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223871-A1 | Thiophene-and thiazolesulfonamides as antineoplastic agents | TPMT, TST, MGMT | OPRD1 4641/4885CA1 1002/4885CA2 1394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.